Navigation Links
TriReme Medical Inc. Receives CE Marking for Antares(TM) Coronary Stent System
Date:10/10/2008

PLEASANTON, Calif., Oct. 10 /PRNewswire/ -- TriReme Medical Inc. (TMI) announced today that it has been authorized to affix the CE (Conformite Europeenne) marking and commercialize in Europe the Antares(TM) Coronary Stent System, a unique main vessel stent system specially designed for use at or near coronary bifurcations.

Representing the next generation in bifurcation stenting, the Antares(TM) system has potential use in a quarter of the 2.2 million angioplasty procedures performed annually worldwide. Antares(TM) stents are not yet approved in the United States and are limited by Federal law to investigational use.

"We are very pleased to achieve this significant milestone that allows commercialization of our Antares(TM) stent system in Europe," said Eitan Konstantino, PhD, President and Chief Executive Officer of TMI. "We believe that the Antares(TM) stent system represents a breakthrough in the treatment of patients suffering from coronary artery disease at or near bifurcations.

"I like the Antares(TM) system concept. The system is designed to fit all classes of bifurcation lesions, irrespective of the size and angulation of the side-branch," said Professor Carlo Di Mario from Royal Brompton Hospital in London. "The operator does not need to commit to a pre-determined side branch treatment and has the flexibility to do what is right for the patient."

Lesions at or near side branches in the coronary tree pose multiple challenges to interventional cardiologists. Combining a low profile stent with a proprietary delivery system, the Antares(TM) system provides a unique set of solutions to the challenges of bifurcation stenting. It can be delivered and deployed in a single step while maintaining access to the side branch and scaffolding the ostium, or the origin of the side branch. As a result, the cardiologist has greater flexibility of treatment options, with the freedom to deploy a second stent in the side branch when additional support is necessary.

"The Antares(TM) stent system is an elegant solution to treat bifurcation lesions that is focused on the main vessel," observed Alexandre Abizaid, MD, PhD, Chief of Coronary Interventions at the Institute Dante Pazzanese of Cardiology in Sao Paulo, Brazil. Dr. Abizaid continued, "It increases operators' confidence by providing continuous side branch access throughout the procedure."

About TriReme Medical Inc.

TriReme Medical Inc. (TMI) is a privately held medical device company backed by Three Arch Partners and Adams Street Partners. TMI is based in California and dedicated to the development and manufacturing of novel stent technology for the treatment of atherosclerotic disease at or near bifurcations.


'/>"/>
SOURCE TriReme Medical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Globus Medical Raises $110 Million in Series E Financing Round
5. Quark Pharmaceuticals Appoints New Chief Medical Officer
6. Boston University Biomedical Engineers Find Chink in Bacterias Armor
7. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
8. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
9. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
10. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
11. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017  Cogentix Medical, ... focused on providing the Urology, Uro/Gyn and Gynecology ... that Ash Keswani has joined the Company as ... this newly created position, Mr. Keswani will report ... CEO. "Our organization is delighted that ...
(Date:4/20/2017)... April 20, 2017 Research and Markets has ... Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage of ... ... delivery technologies will rise from USD 20 Billion in 2015 to ... Drug Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market ...
(Date:4/20/2017)... 2017 Eyevensys, a private biotechnology ... gene expression technology that enables the safe, local, sustained ... a wide range of ophthalmic diseases, announces it has ... Regulatory Agency (MHRA) to advance its technology into clinical ... The ...
Breaking Medicine Technology:
(Date:4/21/2017)... , ... April 21, 2017 , ... Providing broad access ... in opposition, but there is a better way to address this problem. , That ... of Pharmacy, Public Policy and Economics at the University of Southern California, who served ...
(Date:4/21/2017)... ... , ... Brady (NYSE:BRC), a global leader in industrial and safety ... vinyl label materials received certification for the BS5609 British Marine Standard. This internationally ... legible, for use on chemical drums shipped by sea. , “Achieving BS5609 ...
(Date:4/21/2017)... ... April 21, 2017 , ... The VIA Agency , ... for Theravent, Inc. , the makers of a revolutionary new device clinically ... is now working to expand distribution in anticipation of a national launch. VIA ...
(Date:4/21/2017)... , ... April 21, 2017 , ... ... announced an exciting new partnership with the highly regarded and well renowned Asian ... highly innovative, myTAP & myTAP PAP Nasal Pillow Mask, and will stabilize and ...
(Date:4/21/2017)... ... April 21, 2017 , ... BrightStar Care Salt Lake City, a home ... of Utah (APCUT) and has appointed Rex Wheeler as its new Director of Business ... our agency and our ability to provide quality care to the community,” said Tammara ...
Breaking Medicine News(10 mins):